Prestigious International Annual Awards Program Honors Standout AI and Machine Learning Solutions and Companies
DENVER – June 21, 2023 -- Cleerly, the company creating a new standard of care for heart disease, today announced that it has been named “Best Overall AI Solution” in the sixth annual AI Breakthrough Awards program conducted by AI Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market today.
Cleerly’s digital care platform helps physicians precisely identify, define, and treat heart disease at its earliest stages, when it is most treatable. The platform leverages non-invasive coronary computed tomography angiography (CCTA) to perform comprehensive coronary artery phenotyping through AI-powered and FDA-cleared solutions. This technology is based on millions of annotated lab images used to build more than two dozen proprietary algorithms capable of quantifying and characterizing the presence, extent, severity, and type of coronary artery disease (CAD) and other cardiovascular disorders.
Using Cleerly’s advanced machine learning and AI, providers can perform comprehensive assessments of a patient’s CCTA, studying each artery and branch. This assessment shows a patient’s risk of CAD and takes just seven minutes. The diagnostic tools and reporting solutions are tailored to all stakeholders in the heart care pathway, including patients, and the personalized reporting allows providers to deliver precision treatment.
“I believe that a world without heart attacks is achievable in our lifetime. Using AI to drastically reduce the time it takes to identify health issues and ultimately identify every individual at risk of heart disease and prevent heart attacks before they occur is possible with our solution and the continuing refinement of it,” said James K. Min, MD, FACC, FESC, MSCCT, founder and CEO of Cleerly. “We’re grateful AI Breakthrough recognizes the importance of our work as we strive to emulate the world’s most successful preventive care paradigms in medicine, which have historically been in early cancer detection.”
The mission of the AI Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of AI and machine learning related categories, including Generative AI, Computer Vision, AIOps, Deep Learning, Robotics, Natural Language Processing, industry specific AI applications and many more. This year’s program attracted more than 3,200 nominations from over 20 different countries throughout the world.
“Cleerly’s breakthrough use of AI makes them our choice for the ‘Best Overall AI Solution.’ What sets them apart is their technology allows for whole-heart quantification and characterization of actual heart disease as opposed to surrogate or indirect markers of heart disease,” said James Johnson, managing director, AI Breakthrough. “By leveraging AI for advanced imaging, Cleerly is pioneering the transformation of heart disease by using this approach towards precision prevention and paving the way for a new future of cardiovascular care.”
Cleerly is the company creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly helps enable comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway.
For more information, please visit: https://cleerlyhealth.com
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the AI Breakthrough Awards program is devoted to honoring excellence in Artificial Intelligence technologies, services, companies and products. The AI Breakthrough Awards provide public recognition for the achievements of AI companies and products in categories including AI Platforms, Robotics, Business Intelligence, AI Hardware, NLP, Computer Vision and more. For more information visit AIBreakthroughAwards.com.
Download: PNG |
Cleerly: March 26, 2024
CREDENCE and PACIFIC-1 study data demonstrate potential power of AI-QCT ISCHEMIA
Cleerly: March 5, 2024
Company’s AI-enabled technology for future heart attack risk assessment accepted into FDA’s TAP Pilot and to be validated in landmark TRANSFORM trial
Cleerly: February 22, 2024
FDA-cleared Cleerly ISCHEMIA will assist healthcare professionals in clinical diagnosis and decision making for coronary artery disease
Cleerly
